Gregory B. Brown, M.D. has served as our Board Chair since April 2024 and has served as a member of our Board of Directors since March 2007. From February 2020 to April 2026, Dr. Brown served as Chief Executive Officer of Memgen, Inc., a private development-stage biotechnology company, where he remains a director. Dr. Brown is also a co-founder at HealthCare Royalty Partners, or HCR Partners, and is a member of that firm s Senior Advisor Board. Educated as a transplantation immunologist and trained as a thoracic and vascular surgeon, Dr. Brown practiced thoracic and vascular surgery in a community setting where he also founded and led a health maintenance organization. Before co-founding HCR Partners, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm s royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown currently serves on the boards of Lisata Therapeutics, Inc. (Nasdaq:LSTA) and Adimab, LLC, a privately-held company which is a leader of therapeutic antibody discovery and engineering technologies, and previously served on the boards of Faron Pharmaceuticals, Oy (LON:FARN), Cambrex Corporation (formerly, NYSE:CBM) and FAST BioMedical, a privately-held company developing late clinical-stage medical technology. Dr. Brown holds a B.A. from Yale University, an M.D. from SUNY Upstate Medical Center and an MBA from Harvard Business School. Our Board believes that Dr. Brown s extensive experience in the pharmaceutical industry and investing in life sciences companies, as well as his medical and scientific background, qualifies him to serve on our Board of Directors.